Physician profile
Andrew Gdowski
NPI 1508362179
$3,874.81
in general payments reported to CMS, 2019-2025
40 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.95 · 2023: $270 · 2024: $805 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908 · Long Term Medical Supply Or Device Loan: $698 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.22 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $168.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $829.37 | 2024-2025 | |
| Daiichi Sankyo INC. | $332.17 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Regeneron Healthcare Solutions, INC. | $239.91 | 2024-2025 | Libtayo, Lynozyfic |
| Tempus Ai, INC | $209.62 | 2024-2025 | Xt Cdx |
| Janssen Biotech, INC. | $196.64 | 2023-2025 | Darzalex, Rybrevant, Erleada |
| Exelixis INC. | $179.12 | 2023-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $175.89 | 2024-2025 | Enhertu, Imfinzi, Imjudo |
| Pfizer INC. | $175.13 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $138.96 | 2024-2025 | Opdivo |
| Incyte Corporation | $129.00 | 2021-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $108.90 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Gilead Sciences, INC. | $96.48 | 2025 | Trodelvy |
| Astellas Pharma US INC | $93.88 | 2024-2025 | Xtandi, Padcev |
| Celgene Corporation | $92.91 | 2024-2025 | Reblozyl |
| Seagen INC. | $78.75 | 2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gdowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.